By {{ authorText(item) }}

{{ item.publicationDate }}

  • Stefan Oschmann Stefan Oschmann

    A five-point plan against pandemics

    Op-ed by Stefan Oschmann, CEO of Merck KGaA, Darmstadt, Germany, and Wolfgang Ischinger, Chairman of the Munich Security Conference, in "EURACTIV" and “Handelsblatt“ from March 30, 2020
    Read the full article
  • innovation center innovation center

    A Message from the Executive Board

    "All of us at Merck KGaA, Darmstadt, Germany, 57,000 people in 66 countries, are dedicated to serving patients, scientists and customers around the globe."
    Read more

All stories at a glance

Statement on Rebif® (interferon beta-1a) contribution to the US National Institute of Allergy and Infectious Diseases for the ACTT 3 trial

Merck KGaA, Darmstadt, Germany statement on Rebif® (interferon beta-1a) contribution to the US National Institute of Allergy and Infectious Diseases for the ACTT 3 trial

New Report Identifies Paths to Pandemic Resilience

A new report details potential paths to solutions to overcoming the global Covid-19 crisis and ways to prepare for or even prevent a future pandemic.

Merck KGaA, Darmstadt, Germany, and Baylor College of Medicine Collaboration

Merck KGaA, Darmstadt, Germany, and Baylor College of Medicine, Houston, Texas, USA, announced an extension of their ongoing collaboration to advance a manufacturing platform to fight Covid-19.

Masks-Donation

Merck KGaA, Darmstadt, Germany, Donates two Million N95 Medical Grade Masks

First Clinical Trial of TLR7 and 8 Inhibitor as a Potential Treatment for Severe Symptoms

Merck KGaA, Darmstadt, Germany announced the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug application for M5049 for the treatment of patients with Covid-19 pneumonia.

Merck KGaA, Darmstadt, Germany, is Supporting Darmstadt in the COVID-19 Crisis

Merck KGaA, Darmstadt, Germany, is Supporting Darmstadt in the COVID-19 Crisis

Merck KGaA, Darmstadt, Germany Announces its Support of Jenner Institute Reaching first...

Merck KGaA, Darmstadt, Germany and The Jenner Institute announced that The Jenner Institute has laid the foundation for large-scale production of its Covid-19 vaccine candidate, ChAdOx1 nCoV-19.

Merck KGaA, Darmstadt, Germany statement on Rebif® donation to the WHO

As a company dedicated to human progress and to making a lasting difference on patients’ lives, Merck KGaA, Darmstadt, Germany is fully committed to contributing to solutions related to global health crises.

Merck KGaA, Darmstadt, Germany, donates 150,000 Liters of Disinfectant

Merck KGaA, Darmstadt, Germany, donates 150,000 Liters of Disinfectant to the State of Hesse

Merck KGaA, Darmstadt, Germany, statement on Rebif (interferon beta-1a) donation to INSERM

As Merck KGaA, Darmstadt, Germany is a company that is dedicated to human progress and to making a lasting difference on patients’ lives, we are fully committed to contributing to solutions related to global...